{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.3","upperLimit":"23.5","value":"21.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression was defined as any one or more of the following:\n\nAn increase of 25% from lowest confirmed response in:\n\n* Serum M-component (absolute increase \\>= 0.5g/dl)\n* Urine M-component (absolute increase \\>= 200mg/24hour\n* Difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl\n* Bone marrow plasma cell percentage (absolute increase of \\>=10%)","dispersionType":"95% Confidence Interval","groups":[{"description":"Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression Intervention: Drug: melphalan 5mg/m\\^2 orally days 1-4 every 28 days until progression Intervention: Drug: prednisone 60mg/m\\^2, orally days 1-4 every 28 days until progression","id":"OG000","title":"Treatment (Lenalidomide, Melphalan, Prednisone)"}],"paramType":"MEDIAN","populationDescription":"Phase 2 patients","reportingStatus":"POSTED","timeFrame":"registration to progressive disease (up to 3 years)","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}